Brokerages Set Marker Therapeutics, Inc. (NASDAQ:MRKR) PT at $10.17

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $10.1667.

A number of research firms have issued reports on MRKR. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. HC Wainwright assumed coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR opened at $1.66 on Tuesday. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The stock has a market capitalization of $27.67 million, a price-to-earnings ratio of -1.35 and a beta of 1.44. The company’s 50 day simple moving average is $1.61 and its 200 day simple moving average is $1.26.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.The firm had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, analysts anticipate that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently bought and sold shares of MRKR. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics during the third quarter valued at about $25,000. Two Sigma Investments LP bought a new position in Marker Therapeutics in the 3rd quarter valued at approximately $33,000. Jane Street Group LLC acquired a new stake in Marker Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Boyer Financial Services Inc. bought a new stake in Marker Therapeutics during the 4th quarter worth approximately $57,000. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.